BRIEF-Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial

PUBLISHED: Thu, 28 Jan 2021 21:12:09 GMT
Share

Jan 28 (Reuters) –

* NOVAVAX SAYS COVID-19 VACCINE CANDIDATE NVX-COV2373 MET PRIMARY ENDPOINT, WITH VACCINE EFFICACY OF 89.3%, IN PHASE 3 CLINICAL TRIAL CONDUCTED IN UK

* NOVAVAX SAYS NVX-COV2373 SHOWED STRONG EFFICACY IN PHASE 3 UK TRIAL WITH OVER 50% OF CASES ATTRIBUTABLE TO NOW-PREDOMINANT UK VARIANT

* NOVAVAX SAYS VACCINE DEMONSTRATES CLINICAL EFFICACY AGAINST COVID-19 AND BOTH UK AND SOUTH AFRICA VARIANTS

* NOVAVAX SAYS CLINICAL EFFICACY SHOWN IN PHASE 2B SOUTH AFRICA TRIAL WITH OVER 90% OF SEQUENCED CASES ATTRIBUTABLE TO SOUTH AFRICA ESCAPE VARIANT

* NOVAVAX SAYS VACCINE CANDIDATE STABLE AT 2°C TO 8°C (REFRIGERATED) & IS SHIPPED IN READY-TO-USE LIQUID FORMULATION

* NOVAVAX – ADDITIONAL ANALYSIS ON UK, SOUTH AFRICA TRIALS ONGOING, WILL BE SUBMITTED TO PEER-REVIEWED JOURNAL FOR PUBLICATION

* NOVAVAX – SOUTH AFRICA CLINICAL TRIAL ACHIEVED PRIMARY EFFICACY ENDPOINT IN OVERALL TRIAL POPULATION, INCLUDING HIV-POSITIVE & HIV-NEGATIVE SUBJECTS

* NOVAVAX – EXPECTS TO SELECT IDEAL CANDIDATES FOR A BOOSTER AND/OR COMBINATION BIVALENT VACCINE FOR NEW STRAINS IN COMING DAYS

* NOVAVAX – PLANS TO INITIATE CLINICAL TESTING OF NEW VACCINES IN Q2 Source text for Eikon:

(c) Copyright Thomson Reuters 2021. Click For Restrictions – https://agency.reuters.com/en/copyright.html

Sign Up for Our Newsletter Daily Update
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.